Using Methylphenidate to Treat Adults with ADHD
Methylphenidate in Adults With Attention Deficit/Hyperactivity Disorder
PHASE4 · Hospital de Clinicas de Porto Alegre · NCT02951754
This study is testing how well a common ADHD medication called Methylphenidate works for adults and if certain factors can help predict who will benefit from it.
Quick facts
| Phase | PHASE4 |
|---|---|
| Study type | Interventional |
| Enrollment | 600 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Hospital de Clinicas de Porto Alegre (other) |
| Locations | 1 site (Porto Alegre, Rio Grande do Sul) |
| Trial ID | NCT02951754 on ClinicalTrials.gov |
What this trial studies
This study investigates the effectiveness of Methylphenidate (MPH), a common treatment for adults with Attention-Deficit/Hyperactivity Disorder (ADHD). It aims to identify clinical and genetic factors that predict how well patients respond to MPH, given the variability in treatment outcomes. Participants will receive immediate-release MPH while researchers will monitor their responses and tolerability. The study seeks to enhance understanding of personalized treatment approaches for ADHD in adults.
Who should consider this trial
Good fit: Ideal candidates are White Brazilian adults of European descent diagnosed with ADHD who are eligible for immediate-release Methylphenidate treatment.
Not a fit: Patients with contraindications for Methylphenidate, current stimulant treatment, or significant neurological diseases may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more tailored and effective treatment strategies for adults with ADHD.
How similar studies have performed: Previous studies have shown that Methylphenidate is effective for ADHD, but this study's focus on genetic predictors is a novel approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * White Brazilian of European descent * Fulfillment of the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, (DSM-IV) diagnostic criteria for ADHD * Eligibility to immediate-release MPH (IR-MPH) treatment Exclusion Criteria: * Contraindication for IR-MPH use * Current stimulant treatment * Evidence of a clinically significant neurological disease that might affect cognition (e.g., delirium, dementia, epilepsy, head trauma, and multiple sclerosis) * Current or past history of psychosis * Estimated intelligence quotient score lower than 70
Where this trial is running
Porto Alegre, Rio Grande do Sul
- Program on Attention-Deficit/Hyperactivity Disorder (PRODAH); Hospital de Clínicas de Porto Alegre — Porto Alegre, Rio Grande do Sul, Brazil (RECRUITING)
Study contacts
- Principal investigator: Eugênio H Grevet, MD, PhD — Hospital de Clínicas de Porto Alegre
- Study coordinator: Eugênio H Grevet, MD, PhD
- Email: ehgrevet@gmail.com
- Phone: +55 51 3359-8094
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Attention Deficit Disorder With Hyperactivity, ADHD, Adults, treatment, Methylphenidate